Hilleman Laboratories is a joint-venture between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in Child Health.

1. Our commitment to Global Health

2. WELCOME TO HILLEMAN LABORATORIES
Bridging scientific research and industry to
develop effective, affordable and sustainable
vaccines for developing world.

3. Developing Vaccines for Global
Health

4. Tomorrow... is our concern and we care

5. Developing immunity.. Promising well being

6. Life is precious.. Vaccination to preserve it

7. Protecting life and ensuring healthy growth

8. Affordable and accessible vaccines for
the developing nations

9. OUR IDENTITY
Hillemanlabs @ Nanotechnology Building, Jamia Hamdard
Striving towards a healthier world since September 2009
Joint Initiative to build a vaccine R&D facility with focus on developing world
Devoted team of 30 scientists with expertise in Vaccine Development and Testing
Operating with core divisions of Upstream, Downstream, Formulations
and Analytical Labs
Mission to develop thermo stable, efficacious and affordable vaccines

10. DR. MAURICE HILLEMAN
A Pioneer in Vaccine Development
"Discoveries of the cause
for diseases and their
prevention by vaccines...
have been a hallmark for
twentieth century medicine
and provide a remarkable
heritage for the people of
the future."
Maurice R.Hilleman, PhD, DSc
Senior Vice President, 1957-1984
Merck Sharp & Dohme Research Laboratories

11. OUR APPROACH
HL carries out R&D and Clinical Assessment
activities to develop vaccines for diseases that
constitute almost 90% of the global burden of
diseases
HL carries out R&D and Clinical Assessment
activities to develop vaccines for diseases that
constitute almost 90% of the global burden of
diseases
HL is forging partnerships with Government, Policy
Makers, Public & Private Enterprises, Research
Institutes and NGOs to strengthen public health
systems and immunization programs
HL is forging partnerships with Government, Policy
Makers, Public & Private Enterprises, Research
Institutes and NGOs to strengthen public health
systems and immunization programs

12. OUR APPROACH

13. Apply
Focus
Partner
OUR VISION
Philanthropy
Science
Business

14. OUR DREAM
Vaccine for every child
Immunize and protectHealthier force of tomorrow

15. Facility (GLP class)
Scientists
Infrastructure
Novel Immunization
Platform (HL)
OUR COMMITMENT
Reduced
footprint and
affordability
Thermostability
Ease of
administration

16. OUR ADVISORS
(Director, Emory
Vaccine Center)
Dr. Rafi Ahmed
Executive Director,
Icddr,b Dhaka,
Bangladesh
Dr. John Clemens
(Prof. & Chairman
Dept. of Pediatrics
& Child Health,
Aga Khan UMC,
Pakistan)
Dr. Zulfiqar Bhutta
(Assistant Director-
General, Health
Systems and
Innovation)
Dr. Marie-Paule
Kieny
(Board Member and
Advisor for
Foundations in
Switzerland, Uganda,
Thailand and US)
Timothy Nielander
(CEO, The Global
Partnership for
Education)
Alice Albright
(President & Chief
Executive Officer,
Vedantra)
Dr. Allan Shaw
(Chairman, African
Leaders Malaria
Alliance and
Chairman, Board
AIDS Fund)
Ms. Joy Phumaphi
(President, Health
Foundation of
India)
Dr. K. Srinath
Reddy
Ms. Helen Rees
Professor of Medicine, Global
Health, and Pediatrics
Associate Director, Emory
Vaccine Center
Director, Emory Vaccine Policy
and Development
Walter A. Orenstein, MD
Professor Helen Rees OBE
MB BChir, MA (CANTAB),
MRCGP, DCH, DRCOG
Mr. Michel Greco
Former President of
Aventis Pasteur

17. OUR BOARD MEMBERS
Director, Hilleman Laboratories
(Senior Vice President and Head, Global
Vaccine Franchise, Merck)
Dr. James R. Baker
Director, Hilleman Laboratories
(President – Vaccine Division,
Merck)
Dr. Julie Gerberding
Director, Hilleman Laboratories
(Director – Technology Transfer,
Wellcome Trust)
Dr. A.E. Bianco
Director, Hilleman Laboratories
(Senior Vice President, Manufacturing
Division, Merck)
Sanat Chattopadhyay
Director, Hilleman Laboratories
(Chief Operating Officer,
Wellcome Trust)
Simon Jeffreys
(Chairman, Hilleman Laboratories)
Dr. Gerd Zeittlmeissl
Director – Hilleman Laboratories
(Head of Microbial Pathogenesis
(Sanger Center))
Prof. Gordon Dougan

18. OUR MANAGEMENT
Chief Executive
Officer (MSD
Wellcome Trust,
Hillemanlabs)
Dr. Davinder Gill
Vice President -
Finance & Company
Secretary, (MSD
Wellcome Trust,
Hillemanlabs)
Mr. Naveen K Amar
Vice President - HR,
Admin & IT, (MSD
Wellcome Trust
Hillemanlabs)
Mr. Jaideep
Mukherjee Vice President -
Business Development
(MSD Wellcome Trust,
Hillemanlabs)
Mr. Atin Tomar
Vice President – R&D
Dr. Zimra Israel

19. VACCINE RESEARCH OVERVIEW
01 02 03 04
05 06 07 08
Antigen Identification
Candidate screening
Responsiveness
Host Protection
Immunogenicity
Toxicity
Selection
Immune response
Responsiveness in large cohort
Antigen Production
(Laboratory-scale)
Screening of growth medium
Screening of growth parameters
Manufacturing
(Industrialscale)
Process Scale-up
Process optimization
Clinical Trail (Phase I)
Safety
Non-endemic Healthy Adults> 20
About 3 months
Adverse effects
Clinical Trial (Phase II)
Immunogenicity
Endemic infected/noninf.>100
About 3 years
Immune responses
Clinical Trail (Phase III)
Efficacy
Endemic infected/healthy>1000
Up to 5 years Protection

20. VACCINE RESEARCH OVERVIEW
Hilleman Laboratories works extensively to
bridge the gap between current vaccine
candidate reliance on cold chain and low
accessibility & build a new platform technology
for development of thermo-stable and
affordable vaccines

21. The current project undertaken at Hilleman Laboratories is to
heat stabilize the existing vaccine candidate
Development of a thermo-stable oral thin film or granule-
based rotavirus vaccine to allow for greater stability and
reduce cold chain burden
Hilleman laboratories is open to collaboration for development
of innovative vaccine delivery methods to develop the initial
assay for the project
Hilleman Labs first project to focus on affordable access to
life-saving Rotavirus vaccine to resource limited nations
R&D AT HILLEMAN LABORATORIES

22. Microbial and Mammalian culture Filtration and chromatographic
separation
Formulation development and
lyophilization/spray-dryiing
R&D AT HILLEMAN LABORATORIES
Screening and Identifying potential candidates with focus on heat stabilization
Seeding virus – cell culture – potency assay – Formulation Development
Pre-clinical evaluation – viability for commercial scale-up – Development of Delivery technology
Up-Stream Process Downstream Process Formulation & Analytics

23. Marketing and
Distribution
Phase 3
Large Scale
Manufacturing
Late Development
Phase IIIClinical Trial
-> Registration
R&D AT HILLEMAN LABORATORIES
Phase 2
Early Development
Lead –> Phase I /II
Clinical Trial
Phase 1
Basic Research Target
-> Lead Candidate

24. R&D AT HILLEMAN LABORATORIES
Global
Vaccine
Needs
Feasibility
Hilleman
Strengths
Trans-HL management and
advisory group consultation for
program synergy
HL Lead Project
HL Scientific
Advisory
Leadership
Projects adopted
HL Leadership
Program Plan
Review
Review Strengths,
Weakness
Research Proposal
(from extramural,
intramural, biotech,
foundation)

25. R&D AT HILLEMAN LABORATORIES
Up-Stream Process Downstream Process Analytical

26. OUR CULTURE

27. Latest happenings
Best Industrial
Partnership in India

28. HOW WE PERCEIVE THE FUTURE

29. HILLEMAN LABORATORIES PVT. LTD.
Hilleman Laboratories Pvt. Ltd.
2nd Floor, Nanotechnology Building,
Jamia Hamdard, Hamdard Nagar,
New Delhi – 110062
India.
Ph: +91 (11) 3099 7700
Fax: +91 - (11) 3099 7711
Email: bd@hillemanlabs.org
Website: www.hillemanlabs.org
Office Contact: